

## CURRICULUM VITAE

### Jake Ferro Hooper

Department of Psychology

University of Oregon

Eugene, OR, 97403

[jakehoop1@gmail.com](mailto:jakehoop1@gmail.com) | [jakehoop@uoregon.edu](mailto:jakehoop@uoregon.edu)

(240)-409-2460

## EDUCATION

---

### University of Oregon, Eugene, OR

Master of Science, Cognitive Neuroscience | Psychology

2027

Doctor of Philosophy, Cognitive Neuroscience | Psychology

2030

### Virginia Tech, Blacksburg, VA

Bachelor of Science, Cognitive and Behavioral Neuroscience | Psychology

2021

## PUBLICATIONS

---

1. Hutchison KE, **Hooper JF**, Karoly H. (2025) Psilocybin Outside the Clinic: Anticipating the Public Health Challenges of Increasing Publicity, Accessibility, and Use. *JAMA Psychiatry*. [Accepted]
2. **Hooper JF**, Ellingson JM, Hutchison KE. (2025) Preliminary Validation and Refinement of the Psychedelic Aesthetic Experience Questionnaire. *Frontiers in Psychology*. 2025 September 15; 2025;16:1648968 doi: 10.3389/fpsyg.2025.1648968.
3. **Hooper JF**, Stoliker D, Wolfe K, Hutchison KE. Neuroaesthetics of the psychedelic state. *Neuropsychologia*. 2025 Jul 26;109238. doi: 10.1016/j.neuropsychologia.2025.109238.
4. **Hooper JF**, Gyongyosi EL, Hutchison KE, Mueller RL. Aesthetic quality of psychedelic experience is linked to insight and psychological outcomes. *Frontiers in Psychology*. 2025 May 15;16:1533055. doi: 10.3389/fpsyg.2025.1533055.
5. Mueller RL, **Hooper JF**, Ellingson JM, Olsavsky AK, Rzasa-Lynn R, Bryan AD, Bidwell LC, Hutchison KE. A preliminary randomized trial of the safety, tolerability, and clinical effects of hemp-derived cannabidiol in alcohol use disorder. *Frontiers in Psychiatry*. 2025 Apr 28;16:1516351. doi: 10.3389/fpsyt.2025.1516351.
6. **Hooper JF**, Williams S, Mueller R, Hutchison KE. (2025) Age and cannabis co-use moderate psilocybin experience and perceived benefits. *Journal of Psychoactive Drugs*. [Under review]
7. **Hooper JF**, Juliani A, Aqil M, McGovern HT. (2025) Art as a Vehicle for Archetypal Transmission: Synthesizing Interdisciplinary Perspectives. *Brain and Behavioral Reviews*. [In preparation]

## PRESENTATIONS

---

1. **Hooper, JF**. *Art as a Vehicle for Archetypal Transmission*. Invited talk at the Theoretical Neurobiology (TNB) Group, Active Inference Institute. 2025 June 30. [Oral presentation].
2. **Hooper JF**, Spencer JK, Hutchison K. *The Relationship Between Cannabis Use with Psilocybin and Psychological Outcomes*. University of Colorado Department of Psychiatry Research Symposium; 2025 March 19; Aurora, CO.
3. **Hooper JF**, Krause A, Spencer JK. *Research in Psychiatry: Cannabis, Health, and Addiction Over the Lifespan*. Psychiatry Undergraduate Research Program and Learning Experience (PURPLE) Didactic Session; 2024 June 28; Denver, CO. [Oral presentation].

4. **Hooper JF**, Wolfe K, Gyongyosi E. *Psychedelic Neuroaesthetics: A Review and Commentary*. 27th Annual Research and Creative Activities Symposium (RaCAS); 2024 April 26; Denver, CO. [Oral presentation]
5. **Hooper JF\***, Gyongyosi E\*, Hutchison K. *Behavioral Improvement After Psychedelic Use*. Anschutz Department of Medicine 5th Annual Research Day; 2024 April 23; Aurora, CO.
6. **Hooper JF**, Gyongyosi E, Williams S, Hutchison K. *Age-Related Differences in Challenging Psychedelic Experiences*. University of Colorado Department of Psychiatry Research Symposium; 2024 March 20; Aurora, CO.
7. Spencer JK, Krause A, Mueller R, Williams S, **Hooper JF**, Hutchison K. *Psychedelics & Personality: Understanding the Therapeutic Potential*. University of Colorado Department of Psychiatry Research Symposium; 2024 March 20; Aurora, CO.
8. Krause A, Spencer JK, **Hooper JF**, Williams S, Hutchison K. *Psilocybin in Psychiatry: Exploring the Risks & Rewards*. University of Colorado Department of Psychiatry Research Symposium; 2024 March 20; Aurora, CO.
9. Williams S, Gyongyosi E, **Hooper JF**, Hutchison K. *The Effect of Music on Psychedelic Experience*. University of Colorado Department of Psychiatry Research Symposium; 2024 March 20; Aurora, CO.
10. **Hooper JF\***, Gyongyosi E\*, Williams S, Mueller R, Hutchison K. *Cannabidiol Reduces the Experience of Pain in Individuals with Chronic Pain*. 38th Annual Student Research Forum Poster Presentations; 2023 December 05; Aurora, CO.
11. **Hooper JF**, Williams S, Mueller R, Hutchison K. *Cannabidiol Reduces Drinking Behavior and Negative Emotion in Individuals with Alcohol Use Disorder*. CCTSI CU-CSU Summit; 2023 August 16; Denver, CO.
12. Williams S, **Hooper JF**, Mueller R, Hutchison K. *Cannabidiol Effects on Alcohol Cravings and Mental Health in Individuals with Alcohol Use Disorder*. CCTSI CU-CSU Summit; 2023 August 16; Denver, CO.
13. **Hooper JF**, Williams S, Mueller R, Hutchison K. *Cannabidiol Reduced Impaired Control of Drinking Behavior in Individuals with Alcohol Use Disorder*. University of Colorado Department of Psychiatry Research Symposium; 2023 March 22; Aurora, CO.

\*Shared First Author

## RESEARCH EXPERIENCE

---

### Senior Clinical Research Professional

May 2022 – September 2025

University Of Colorado Anschutz Medical Campus - Aurora, CO

Supervised by Raeghan Mueller, PhD., Kent Hutchison, PhD.

- Coordinate studies involving cannabis, alcohol, geriatric, and opioid populations in FDA-regulated trials within the Department of Psychiatry Division of Addiction Science, Prevention, and Treatment.
- Lead recruitment and screening processes to evaluate participant suitability for studies. Monitor correspondence and attrition rates.
- Design, modify, and implement research techniques, including phlebotomy, cognitive and clinical assessments, sample processing and investigational product dispensing.
- Validate and ensure accuracy and integrity of incoming data, addressing discrepancies and managing adverse event reporting accordingly.
- Conduct data analysis (R, Jamovi, SPSS), manuscript drafting (LaTeX), and literature reviews.
- Develop and maintain research documentation in line with regulatory bodies (IRB, FDA, ICH-GCP) and sponsors (NIA, NIAAA, NIDA).
- Train and oversee a team of 8 research coordinators; supervise tasks and ensure performance quality.
- Spearhead study development and data structuring in REDCap on a cross-sectional study.
- Write and implement R scripts to generate comprehensive data and study tracking reports.

### Clinical Research Coordinator

November 2021 – May 2022

## **University Of Colorado Anschutz Medical Campus - Aurora, CO**

*Supervised by Christopher Mizenko, M.S., Jeffrey Bennett, PhD.*

- Independently coordinated 4 studies in sponsor initiated multisite clinical trials under the neuro-ophthalmology subspecialty within the Department of Neurology.
- Evaluated potential subject participants to assess suitability for planned studies.
- Plan, modify and executed research techniques, procedures and tests including phlebotomy, vitals, ECG, clinical assessment, and investigational product dispense.
- Validated incoming data to check information accuracy while independently locating and correcting concerns.
- Organized participant-informed consent waivers and research scope documentation.

## **Undergraduate Research Assistant**

January 2020 – June 2021

**Clinton Lab At Virginia Tech - Blacksburg, VA**

*Supervised by Matthew Glover, PhD., Sarah Clinton, PhD.*

- Utilized bench protocols and techniques to perform various experimental procedures and sample collection under primary and graduate level investigators.
- Gathered experience in fecal DNA extraction, immunohistochemistry, and microtome.
- Recorded and scored various rat behavior for a study investigating changes in emotional affect due to prenatal SSRI exposure.
- Researched and edited protocol literature reviews.
- Performed statistical, qualitative, and quantitative analysis.

## **Undergraduate Research Assistant**

May 2019 – March 2020

**SCANLAB At Virginia Tech - Blacksburg, VA**

*Supervised by Ligia Antezana, M.S., John Richey, PhD.*

- Aided graduate students with a study investigating emotional affect in children with autism.
- Utilized spreadsheets, R statistical programming, and fMRI image scoring in cleaning data.
- Prepared literature for reports, presentations, or submission to peer-reviewed journals.
- Recorded data and maintained source documentation following good documentation practices.
- Gathered, arranged, and corrected research data to create representative graphs and charts highlighting results for presentations.

## **COORDINATED CLINICAL TRIALS AND STUDIES**

---

1. "ALEXION 19-2038" (sponsored [Alexion], multisite phase 3 RCT investigating a Ravulizumab for treatment of NMOSD). NCT04201262
  2. "SakuraBonsai MN42928" (sponsored [Genentech/Hoffmann-La Roche], multisite phase 4 RCT investigating Satralizumab-mwge [Enspryng] to prevent relapses in people with NMOSD). NCT05269667
  3. "SPHERES NMOSD-750" (sponsor [CorEvitas], multisite patient registry to collect data on natural progression of NMOSD). NCT04886492
  4. "cosMOG 21-3747" (sponsored [UCB Biopharma], multisite phase 3 RCT investigating efficacy of Rozanolixizumab for the treatment of MOG-AD). NCT05063162
  5. "AUD 20-2694" (investigator/NIH-NIAAA funded, single site [pilot] phase 2 RCT investigating efficacy of cannabidiol for the treatment of AUD). NCT04873453
  6. "ECHO 21-5122" (investigator/NIH-NIAAA funded, single site phase 2 RCT investigating the efficacy of cannabidiol to reduce opioid use, anxiety, and pain and improve sleep and cognitive function. NCT05299944
  7. "SONAR 22-1894" (investigator/NIH-NIAAA funded, single site phase 2/3 RCT investigating efficacy of cannabidiol for the treatment of AUD). NCT05613608
  8. "CRANIA 23-0619" (investigator/NIH-NIA funded, single site phase 2 RCT testing the effects of cannabidiol on validated biomarkers of Alzheimer's disease progression, behavioral and clinical measures, with putative mechanisms of CBD action). NCT05822362
  9. "LUNA 22-1427" (investigator/NIH funded, single site phase 2 RCT testing the safety, tolerability, and clinical effects of cannabidiol on traumatic brain injury). NCT05632627
  10. "PEACE 23-1379" (investigator funded, survey study collecting data on naturalistic psychedelic use and subjective health outcomes).
  11. "ALTA 25-0291" (investigator funded, single site observational study collecting data on naturalistic psilocybin use, tryptamine concentrations, subjective effects, and health outcomes).
-

## SKILLS

---

- Data capture management systems (REDCap, Epic, Medidata, Oncore)
- Inventory and supply management.
- Clinical trial management, with direct patient interaction.
- Microsoft Office Suite
- Phlebotomy, vitals
- CITI GCP, Biomedical Research, HIPS, IATA
- Cognitive Assessment (CDR, MoCA, NIH toolbox, RAVLT)
- Clinical Assessment (MINI, PROMIS, C-SSRS)
- Benchwork (microscope, microtome, pipette aliquots, IHC, DNA, centrifuge)
- ECG
- R (data cleaning; data visualization; statistical modelling)
- LaTeX

## HONORS AND AWARDS

---

<b>Dean's List</b> , Virginia Tech	2018-2021
<b>Member Nu Rho Psi</b> , Virginia Tech	2020
<b>Julian Burruss Scholarship Awardee</b> , Virginia Tech	2017-2021
<b>National Educational Foundation 1847 Scholarship Awardee</b> , Virginia Tech	2020
<b>Multidisciplinary Association for Psychedelic Studies (MAPS) Scholarship Awardee</b>	2023, 2025

## CERTIFICATES

---

<b>Certified Phlebotomy Technician (CPT)</b> , NHA	2022
<b>Certified Clinical Dementia Rater (CDR)</b> , Knight ADRC	2022
<b>Certified Basic Life Support Provider (BLS/CPR)</b> , Rocky Mountain CPR	2021